Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2022-003788-13-FI
EUCTR2022-003788-13-FI
Active, not recruiting
Phase 1

Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both? - FAPStera

Heikki Minn0 sites40 target enrollmentAugust 24, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMetastatic prostate cancerTherapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Metastatic prostate cancer
Sponsor
Heikki Minn
Enrollment
40
Status
Active, not recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 24, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
Heikki Minn

Eligibility Criteria

Inclusion Criteria

  • •Men with histologically confirmed prostate cancer. Age 50\-85 years.
  • •WHO performance score 0\-2\.
  • •At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single\-photon emission computed tomography (SPECT) imaging.
  • •All previous treatment lines are allowed.
  • •Patient signs informed consent form after receiving written information.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 10
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •Patient is not able to understand the purpose of the study.
  • •Medical conditions prohibiting whole\-body PET/CT imaging.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerTherapeutic area: Diseases [C] - Male Urogenital Diseases [C12]
CTIS2024-511104-16-00Turku University Hospital40
Completed
Phase 1
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Prostate CancerCancer - Prostate
ACTRN12615000912583Peter MacCallum Cancer Centre30
Completed
Not Applicable
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)
NL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
Completed
Not Applicable
Prostate Cancer Molecular MedicineProstate cancerprostate carcinoma1003859710036958
NL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
Active, not recruiting
Phase 1
Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50